Aripiprazole Contraindication in Parkinson's Disease

Evidence Against Aripiprazole Use

The American Geriatrics Society recommends avoiding aripiprazole in patients with Parkinson's disease due to high risk of motor symptom worsening, as stated in the 2019 Beers Criteria, which only recognizes quetiapine, clozapine, and pimavanserin as acceptable antipsychotics for this population 1
The American Geriatrics Society Beers Criteria explicitly removed aripiprazole from the list of preferred antipsychotics for treating psychosis in Parkinson's disease patients, reflecting accumulating evidence of harm 1

Both aripiprazole and amantadine carry significant CNS toxicity risks that are additive when combined, according to Praxis Medical Insights 2
Amantadine causes CNS side effects in 13% of patients at standard dosing, including nervousness, anxiety, difficulty concentrating, and lightheadedness, with serious toxicity including marked behavioral changes, delirium, hallucinations, agitation, and seizures at higher plasma concentrations, as reported by MMWR Recommendations and Reports 3, 4

The American Geriatrics Society recommends using quetiapine, clozapine, or pimavanserin as the only acceptable antipsychotic options for psychosis management in Parkinson's disease patients, as per the AGS Beers Criteria 1
Optimizing antiparkinsonian medications to reduce psychosis triggers, such as reducing anticholinergics, amantadine, and dopamine agonists before reducing levodopa, is a recommended first-line approach, according to Clinical Nutrition 6